Start Date
December 31, 2024
Primary Completion Date
November 30, 2029
Study Completion Date
April 30, 2032
HB-202/HB-201 alternating 2-vector therapy
Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Placebo
Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Pembrolizumab
Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
Lead Sponsor
Hookipa Biotech GmbH
INDUSTRY